Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma
Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB).
January 7, 2025
by PRNewswire
New regulations in the Year 2023 for different regulatory bodies around the world
This article will explore new regulations in countries like the United States, Europe, Japan, and Australia.
January 23, 2024
by Muhammad Asim Niazi
Drug Marketing in China and Worldwide (July)
On July 6th, Eisai's lecanemab (Leqembi) was fully approved by the FDA for the treatment of Alzheimer's disease
August 11, 2023
by Caicai/PharmaSources
EMA regulation and response to drug shortages
The EMA has established an agency called the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) to address drug shortages.
June 12, 2023
by PharmaSources/zhulikou431
Why Drug regulatory authority updates their Rules and Regulations
Pharmaceutical regulatory authorities regularly update their rules and regulations regarding drug review and approval.
March 21, 2023
by Muhammad Asim Niazi
Pharma Co-packaging Regulations
Let’s discuss some regulatory requirements for contract packaging in line with three most competitive markets i.e China , United States and Europe.
March 21, 2023
by Muhammad Asim Niazi
New regulation strengthens role of EMA in EU crisis response
NEWS
New regulation strengthens role of EMA in EU crisis response
The regulation sees tools, structures and processes set up by EMA during the pandemic to accelerate clinical trial approval and regulatory assessments in the EU being formally recognised.
February 9, 2022
by EuropeanPharmaceuticalReview
Drugmakers Meet With EMA on Vaccines Targeting Omicron
The European Medicines Agency (EMA) is meeting with four leading COVID-19 vaccine makers to discuss potential trials for shots targeting the fast-spreading Omicron variant, as reported in the Financial Post.
January 11, 2022
by FirstWordPharma
Pfizer’s Paxlovid™ can be used for the treatment of COVID-19, says EMA
New European Medicines Agency advice states Paxlovid™ can be used to treat those at high risk of developing severe COVID-19 symptoms.
December 21, 2021
by EuropeanPharmaceuticalReview
EMA CHMP advises use of Pfizer’s Covid-19 oral antiviral Paxlovid
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the usage of Pfizer’s oral antiviral, Paxlovid (nirmatrelvir plus ritonavir), to treat adult Covid-19 patients.
December 20, 2021
by Pharmaceutical-Technology
EMA initiates rolling review of Valneva’s COVID-19 vaccine (VLA2001)
The European Medicines Agency (EMA)’s human medicines committee (CHMP) has begun a rolling review of VLA2001, a COVID-19 vaccine being developed by Valneva...
December 6, 2021
by EuropeanPharmaceuticalReview
EMA receive marketing authorisation application for molnupiravir
The use of molnupiravir in COVID-19 cases aims to reduce the pressure on hospitals, in turn reducing the risk of patients developing more severe symptoms of the virus.
November 26, 2021
by PharmaTimes